重组人血管内皮抑制素联合吉西他滨和顺铂治疗非小细胞肺癌

Endostar combined with gemcitabine and cisplatin in treatment of non-small cell lung cancer

目的:评价重组人血管内皮抑制素+吉西他滨+顺铂治疗老年性晚期非小细胞肺癌(NSCLC)的有效性和安全性。方法:将2007年1月至2010年12月在辽宁省肿瘤医院住院的72例老年性晚期NSCLC患者分为两组,其中研究组(重组人血管内皮抑制素+吉西他滨+顺铂)患者40例;对照组(吉西他滨+顺铂)患者32例,两组患者均至少完成2个周期的治疗。评价两组患者总有效率、临床获益率和不良反应发生情况。结果:研究组和对照组患者有效率、临床获益率分别为42.5%和28.1%、80.0%和56.2%,两组比较,差异有统计学意义(P<0.05);研究组和对照组患者骨髓抑制、胃肠道反应、肝肾功能损害发生率分别为37.5%和37.5%、12.5%和12.5%、7.5%和6.2%,两组比较,差异无统计学意义(P>0.05)。结论:重组人血管内皮抑制素+吉西他滨+顺铂治疗老年性晚期NSCLC是一种有效、安全的方案。

Objective： To observe the efficacy and safety of endostar （Recombinant human endostatin） combined with GP （ cisplatin ＋ gemcitabine） in treatment of advanced non-small cell lung cancer （NSCLC） in the elderly. Methods： From January 2007 through December 2010, 72 elderly advanced NSCLC patients were treated in our department. Endostar plus GP was used in 40 cases （test group） and GP was used in 32 cases （ control group）. Patients in both groups received at least 2 cycles of treatment. The 2 groups were compared in efficacy, clinical benefit rate and adverse events. Results： The test group was significantly superior to the control group in efficacy （42.5% vs 28. 1%） and in clinical benefit rate （80.0% vs 56.2%） （P〈0.05）. The incidences of myelosuppression, gastrointestinal tract reaction （nausea and vomiting ） and liver and kidney functional lesion were respectively 37.5% vs 37.5% , 12.5% vs 12.5% and 7.5% vs 6.2% for the test group and the control group, with no significant differences （ P 〉 0.05 ）. Conclusion ： Endostar with GP for NSCLC treatment in the elderly is safe and practicably effective.